Citius Pharmaceuticals Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Citius Pharmaceuticals de 65.6% y 58.8% respectivamente, mientras que el BPA crecerá en un 65.9% al año.

Información clave

49.9%

Tasa de crecimiento de los beneficios

50.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	19.4%
Tasa de crecimiento de los ingresos	44.8%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	19 Aug 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

DB:47N - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
9/30/2027	353	200	209	209	2
9/30/2026	238	128	160	160	2
9/30/2025	86	15	38	38	3
9/30/2024	N/A	-37	-28	-31	3
6/30/2024	N/A	-40	-29	-29	N/A
3/31/2024	N/A	-37	-30	-30	N/A
12/31/2023	N/A	-39	-30	-30	N/A
9/30/2023	N/A	-34	-29	-29	N/A
6/30/2023	N/A	-31	-29	-29	N/A
3/31/2023	N/A	-31	-27	-27	N/A
12/31/2022	N/A	-28	-29	-29	N/A
9/30/2022	N/A	-34	-28	-28	N/A
6/30/2022	N/A	-31	-68	-28	N/A
3/31/2022	N/A	-29	-65	-25	N/A
12/31/2021	N/A	-26	-59	-19	N/A
9/30/2021	N/A	-25	-64	-24	N/A
6/30/2021	N/A	-24	-22	-22	N/A
3/31/2021	N/A	-21	-21	-21	N/A
12/31/2020	N/A	-21	-21	-21	N/A
9/30/2020	N/A	-18	-17	-17	N/A
6/30/2020	N/A	-17	-16	-16	N/A
3/31/2020	N/A	-17	-16	-16	N/A
12/31/2019	N/A	-16	-15	-15	N/A
9/30/2019	N/A	-16	-12	-12	N/A
6/30/2019	N/A	-15	-12	-12	N/A
3/31/2019	N/A	-12	-11	-11	N/A
12/31/2018	N/A	-13	-11	-11	N/A
9/30/2018	N/A	-13	-11	-11	N/A
6/30/2018	N/A	-13	-12	-12	N/A
3/31/2018	N/A	-13	N/A	-12	N/A
12/31/2017	N/A	-11	N/A	-9	N/A
9/30/2017	N/A	-10	N/A	-8	N/A
6/30/2017	N/A	-10	N/A	-6	N/A
3/31/2017	N/A	-11	N/A	-6	N/A
12/31/2016	N/A	-9	N/A	-7	N/A
9/30/2016	N/A	-8	N/A	-6	N/A
6/30/2016	N/A	-7	N/A	-5	N/A
3/31/2016	N/A	-4	N/A	-3	N/A
12/31/2015	N/A	-3	N/A	-2	N/A
9/30/2015	N/A	-3	N/A	-2	N/A
6/30/2015	N/A	-3	N/A	-2	N/A
3/31/2015	N/A	-2	N/A	-1	N/A
12/31/2014	N/A	-2	N/A	-1	N/A
9/30/2014	N/A	-1	N/A	-1	N/A
6/30/2014	N/A	-1	N/A	-1	N/A
3/31/2014	N/A	-1	N/A	-1	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que 47N sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (0.7%).

Beneficios vs. Mercado: Se prevé que 47N sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que 47N sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (57.3% al año) de 47N crezcan más rápidamente que los del mercado German (5.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (57.3% al año) de 47N crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de 47N se prevé que sea elevada dentro de 3 años.

Citius Pharmaceuticals Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast breakeven date pushed back to 2026

Forecast breakeven date pushed back to 2026

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2024

Forecast breakeven date moved forward to 2023

Recent updates

Citius Pharmaceuticals, Inc. Provides Non-Compliance Update

New minor risk - Market cap size

Citius Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Citius Pharmaceuticals, Inc. Receives FDA Approval for LYMPHIR Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

Citius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $15.000002 million.

Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

New major risk - Share price stability

The Nasdaq Stock Market LLC Grants Citius Pharmaceuticals' Request for an Extension through September 9, 2024 to Evidence Compliance with the Bid Price Rule Pursuant to Nasdaq Listing Rule 5550(a)(2)

Forecast breakeven date pushed back to 2026

Citius Pharmaceuticals, Inc. Announces the Resubmission of the Biologics License Application to the U.S. Food and Drug Administration for Lymphir

New minor risk - Market cap size

Citius Pharmaceuticals, Inc., Annual General Meeting, Mar 12, 2024

Citius Pharmaceuticals, Inc. Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage Catheters

New minor risk - Profitability

Citius Pharmaceuticals, Inc. Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor

Citius Pharmaceuticals, Inc. Announces Changes to its Audit Committee

Citius Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Stock Market

Citius Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Stock Market

Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration Regarding the Planned Resubmission of the BLA for LYMPHIR

Citius Pharmaceuticals, Inc. Reaches 92 Event Milestone in Mino-Lok Phase 3 Trial

Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Citius Pharmaceuticals, Inc. Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

Citius Pharmaceuticals, Inc. Appoints Dennis M. McGrath to Board of Directors

Citius Pharmaceuticals, Inc., Annual General Meeting, Feb 07, 2023

Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

Insufficient new directors

Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma

Insufficient new directors

Citius Pharmaceuticals, Inc. Enrolls First Patient in Phase 2B Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

Citius Pharmaceuticals, Inc. Announces Executive Changes

Forecast breakeven date pushed back to 2024

Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/Ontak (E7777)

Citius Pharmaceuticals Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

Forecast breakeven date moved forward to 2023

Citius Pharmaceuticals, Inc. Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma

Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications

Citius Pharmaceuticals, Inc. (NasdaqCM:CTXR) agreed to acquire Rights and Certain Related Assets of Dr. Reddy's Laboratories Limited (BSE:500124) for approximately $150 million.

Citius Pharmaceuticals, Inc. Announces Positive Recommendation by Independent Data Monitoring Committee to Continue the Mino-Lok® Phase 3 Trial as Planned

Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial

Citius Pharmaceuticals, Inc. Reports Strong Clinical Community Engagement During Mino-Lok Phase 3 Trial-Related Webinar

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento